BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Short (1M)
Elara Capital Recommends 'Accumulate' On Sanofi India
According to Elara Capital, Sanofi India's portfolio is skewed more towards a high-growing chronic portfolio. The company's top products, such as Lantus, Insuman and Allerga, along with line extensions of Amaryl remain resilient, the brokerage adds.